BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33667441)

  • 1. Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
    Clarkson SA; Heindl B; Cai A; Beasley M; Dillon C; Limdi N; Brown TM
    Am J Cardiol; 2021 Jun; 148():1-7. PubMed ID: 33667441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
    JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Long-Term Mortality in Patients With Single Coronary Narrowing and Diabetes Mellitus to That of Patients With Multivessel Coronary Narrowing Without Diabetes Mellitus.
    Omair M; Koshy AN; Dinh DT; Brennan AL; Reid CM; Ajani AE; Duffy SJ; Farouque O; Yudi MB; Clark DJ
    Am J Cardiol; 2021 Mar; 142():1-4. PubMed ID: 33285090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D
    Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
    Tscharre M; Farhan S; Bruno V; Rohla M; Egger F; Weiss TW; Hübl W; Willheim M; Wojta J; Geppert A; Huber K; Freynhofer MK
    Eur J Clin Invest; 2019 Sep; 49(9):e13157. PubMed ID: 31318979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
    Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study.
    Chen Y; Yin T; Xi S; Zhang S; Yan H; Tang Y; Qian J; Chen J; Su X; Du Z; Wang L; Qin Q; Gao C; Zheng Y; Zhao X; Cheng X; Li Z; Zhang W; Chen H; Wang J; Yang Z; Li H; Liu H; Zhou X; Qu B; Xiang D; Guo Y; Wang L; Nie S; Fu G; Yang M; Cai S
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1194-1204. PubMed ID: 31112635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial).
    Alkhalfan F; Nafee T; Yee MK; Chi G; Kalayci A; Plotnikov A; Braunwald E; Gibson CM
    Am J Cardiol; 2020 Mar; 125(5):661-669. PubMed ID: 31898965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
    Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
    Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions.
    Schmucker J; Fach A; Mata Marin LA; Retzlaff T; Osteresch R; Kollhorst B; Hambrecht R; Pohlabeln H; Wienbergen H
    J Am Heart Assoc; 2019 Sep; 8(18):e012530. PubMed ID: 31538856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Åkerblom A; Wojdyla DM; Wallentin L; James SK; de Souza Brito F; Steg PG; Cannon CP; Katus HA; Himmelmann A; Storey RF; Becker RC; Lopes RD;
    Am Heart J; 2019 Jul; 213():57-65. PubMed ID: 31108273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.
    Perera D; Crake T; Lee V
    Crit Pathw Cardiol; 2018 Jun; 17(2):77-82. PubMed ID: 29768315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
    Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW
    JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
    Zheng W; Li Y; Tian J; Li L; Xie L; Mao Q; Tong W; Zhou D; Azzalini L; Zhao X
    Biomed Res Int; 2019; 2019():3170957. PubMed ID: 31016189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
    Wang HY; Cai ZX; Yin D; Yang YJ; Song WH; Dou KF
    Am J Cardiol; 2021 Mar; 142():14-24. PubMed ID: 33285091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention.
    Cai A; Dillon C; Hillegass WB; Beasley M; Brott BC; Bittner VA; Perry GJ; Halade GV; Prabhu SD; Limdi NA
    J Am Heart Assoc; 2019 Nov; 8(22):e012874. PubMed ID: 31701784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina pectoris or non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction) on 2-year outcomes in patients undergoing percutaneous coronary intervention.
    Tang XF; Song Y; Xu JJ; Ma YL; Zhang JH; Yao Y; He C; Wang HH; Jiang P; Jiang L; Liu R; Gao Z; Zhao XY; Qiao SB; Xu B; Yang YJ; Gao RL; Yuan JQ
    J Interv Cardiol; 2018 Feb; 31(1):5-14. PubMed ID: 29023996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.